Brain Disease Biomarker Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden.
PLoS One. 2012;7(11):e50237. doi: 10.1371/journal.pone.0050237. Epub 2012 Nov 28.
There is an urgent need for biomarkers to enable early diagnosis of Alzheimer's disease (AD). It has recently been shown that a variant within the clusterin gene is associated with increased risk of AD and plasma levels of clusterin have been found to be associated with the risk of AD. We, therefore, investigated the diagnostic value of clusterin by quantifying clusterin using an ELISA in plasma from 171 controls, 127 patients with AD, 82 patients with other dementias and 30 patients with depression. We observed similar plasma clusterin levels in controls, AD patients and patients with other dementias, suggesting that plasma clusterin levels have no diagnostic value for AD. There was a slight, but significant, increase in plasma clusterin in patients with depression compared to all other groups tested, which may warrant further investigation.
目前迫切需要生物标志物来实现阿尔茨海默病（AD）的早期诊断。最近有研究表明，载脂蛋白基因中的一个变异与 AD 风险增加有关，并且发现血浆载脂蛋白水平与 AD 风险相关。因此，我们通过 ELISA 定量检测了 171 名对照者、127 名 AD 患者、82 名其他痴呆患者和 30 名抑郁症患者血浆中的载脂蛋白，以评估载脂蛋白的诊断价值。我们发现对照组、AD 患者和其他痴呆患者的血浆载脂蛋白水平相似，提示血浆载脂蛋白水平对 AD 无诊断价值。与所有其他测试组相比，抑郁症患者的血浆载脂蛋白水平略有升高，但有统计学意义，这可能需要进一步研究。
